First deliveries of Astrazeneca - Oxford University COVID-19 vaccine to Malaysia expected in first half of 2021
DEC 22, 2020 @ 10.44PM
The supply agreement between Astrazeneca and Malaysia consist of 6.4 million doses of Covid-19 vaccine.
First deliveries of AstraZeneca-Oxford University's Covid-19 vaccine AZD1222 are expected in the first half of 2021.
Dr Sanjeev Panchal, Country President of AstraZeneca Malaysia said, “AstraZeneca is proud to reinforce our commitment to Malaysia and support the government’s Covid-19 vaccine strategy by providing 6.4 million doses of the AstraZeneca/University of Oxford’s potential vaccine, AZD1222, at no profit during the period of the pandemic. I am grateful for the government’s guidance and leadership, and look forward to deepening our cooperation to fight Covid-19. When the government, private sector and academia join hands, so much can be achieved to protect people's lives and build a healthier Malaysia.” Under this agreement AstraZeneca will expand its global manufacturing capacity to ensure dedicated supply of AZD1222 for Malaysia. This takes place in parallel to the ongoing clinical trials in the US, UK, Brazil, South Africa, Japan and Russia. Results of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet on December 8th 2020, demonstrated that the vaccine is safe and effective at preventing symptomatic Covid-19 and that it protects against severe disease and hospitalisation. To ensure that the potential vaccine lives up the highest safety standards and its introduction complies with the healthcare regulations of Malaysia, the Ministry of Health, Ministry of Science, Technology and Innovation and AstraZeneca are working together on the preparations for swift and science-led regulatory approval. AstraZeneca is working with the University of Oxford, governments, leading health organisations such as WHO, CEPI and GAVI and manufacturers to provide the vaccine broadly, equitably and at no profit during this pandemic. The Advance Purchase Agreement for Malaysia complements hundreds of millions of doses of AZD1222 that are being made available through the COVAX Facility, to which the government of Malaysia is a partner. About AZD1222 AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body. |
EXPLORE FURTHER
|
Pharmacy cautions against self-medication and self-dosing of 'Ivermectin' to treat COVID-19No human use of Ivermectin is approved or registered in Malaysia
|
|
Could a single dose of the drug Ivermectin stop the SARS-COV-2 virus from growing?Ivermectin removed all viral RNA by 48 hours
|
|
The Malaysian response to Covid-19: Building preparedness for ‘surge capacity’, testing efficiency and containmentEarly coordination key to Malaysia's COVID-19 response success
|
|
Is it sinusitis or Covid-19?How COVID-19 symptoms differ from sinusitis: Key insights
|
|
Covid-19: The legal implications of patients' lack of honestyHow can we legally encourage patients to share critical information?
|
|
Road to recovery: Care after COVID-19Understanding post-acute Sequelae of SARS-CoV-2 infection in patients
|
